Georgiamune and Verily have entered a strategic collaboration to advance new cancer treatments.

Verily's molecular and real-world evidence offerings will be leveraged to develop Georgiamune's drug candidates.  

The solution will aid in detecting predictive and outcome biomarkers to develop the new therapeutics. 

Georgiamune and Verily will utilise clinical trial data and longitudinal real-world data sources for enhanced clinical development. 

Initially, the companies will deploy Verily's Immune Profiler to carry out immune mapping of Georgiamune’s dual-functioning antibody, GIM-122. 

This antibody is currently being analysed for tolerability, safety and antitumour activity in a Phase I/II clinical trial for treating checkpoint refractory or resistant advanced solid tumours. 

The Immune Profiler will also be deployed to analyse GIM-122’s pharmacodynamic effect and immune response in patients. 

The collaboration will then be expanded into other cancer assets and treatment areas from Georgiamune, including autoimmune ailments. 

Georgiamune founder and CEO Dr Samir Khleif stated: “Verily’s expertise in immune profiling, real-world data and advanced analytics provide a comprehensive data profile to accelerate the development of our novel drug candidate. 

“This partnership will allow us to focus on identifying the patient population that could potentially benefit the most from our breakthrough discoveries.”